SCHEMBL3764137

SCHEMBL3764137

CCOC(=O)N1CCc2c(sc(NC(=O)c3ccccc3)c2-c2nc3ccccc3s2)C1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.62
KDM4E B2RXH2 3/20 0.62
ALDH1A1 P00352 2/20 0.62
NPC1 O15118 2/20 0.62
NPSR1 Q6W5P4 1/20 0.62
MEN1 O00255 2/20 0.61
HTT P42858 2/20 0.61
KMT2A Q03164 2/20 0.61
TP53 P04637 2/20 0.61
HPGD P15428 1/20 0.61
TSHR P16473 1/20 0.61
APEX1 P27695 9/20 0.59
USP2 O75604 2/20 0.58
POLB P06746 1/20 0.58
RECQL P46063 1/20 0.58
RAB9A P51151 1/20 0.58
BLM P54132 1/20 0.58
LMNA P02545 3/20 0.57
UHRF1 Q96T88 2/20 0.55
ATM Q13315 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1494887 0.93 MAPT (0.58) MAPTKDM4EALDH1A1NPC1NPSR1
SCHEMBL14292152 0.92 KDM4E (0.57) MAPTKDM4EALDH1A1NPC1NPSR1
SCHEMBL1494959 0.91 MAPT (0.56) MAPTKDM4EALDH1A1NPC1NPSR1
SCHEMBL1494835 0.91 APEX1 (0.72) MAPTKDM4EALDH1A1NPC1NPSR1
SCHEMBL1495005 0.90 MAPT (0.69) MAPTKDM4EALDH1A1NPC1NPSR1
SCHEMBL1292258 0.89 TP53 (0.58) MAPTKDM4EALDH1A1NPC1NPSR1
SCHEMBL1495050 0.89 KDM4E (0.66) MAPTKDM4EALDH1A1NPC1NPSR1
SCHEMBL3759398 0.86 LMNA (0.75) MAPTKDM4EALDH1A1NPC1NPSR1
SCHEMBL13833618 0.85 APEX1 (0.80) MAPTKDM4EALDH1A1NPC1NPSR1
SCHEMBL13735656 0.83 APEX1 (0.83) MAPTKDM4EALDH1A1NPC1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100298370-A1 BENZOTHIAZOLYL THIENOPYRIDINE DERIVATIVES AND USES THEREOF RIMONYX PHARMACEUTICALS LTD. (IL) 2010-11-25 US claimed
WO-2008020438-A2 BENZOTHIAZOLYL THIENOPYRIDINE DERIVATIVES AND USES THEREOF RIMONYX PHARMACEUTICALS LTD (IL) 2008-02-21 WO claimed
US-20100298370-A1 BENZOTHIAZOLYL THIENOPYRIDINE DERIVATIVES AND USES THEREOF RIMONYX PHARMACEUTICALS LTD. (IL) 2010-11-25 US disclosed
US-20100298370-A1 BENZOTHIAZOLYL THIENOPYRIDINE DERIVATIVES AND USES THEREOF RIMONYX PHARMACEUTICALS LTD. (IL) 2010-11-25 US disclosed
US-20100298370-A1 BENZOTHIAZOLYL THIENOPYRIDINE DERIVATIVES AND USES THEREOF RIMONYX PHARMACEUTICALS LTD. (IL) 2010-11-25 US disclosed
WO-2008020438-A2 BENZOTHIAZOLYL THIENOPYRIDINE DERIVATIVES AND USES THEREOF RIMONYX PHARMACEUTICALS LTD (IL) 2008-02-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298370-A1 BENZOTHIAZOLYL THIENOPYRIDINE DERIVATIVES AND USES THEREOF HPSE, HDGF, HPGDS MAPT 1611/4885KDM4E 3176/4885ALDH1A1 1539/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.